Biologics in India: bridging the gap

Section 10(4)(ii)(D) of India’s Patents Act, 1970 mandates the disclosure of the source and geographical origin of biological material whenever it’s mentioned in a patent specification but not sufficiently described in it or made available to the public.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Insulin pump rivals face off in major trade secrets dispute hearing

8 January 2026 Important questions about when companies must act on suspicions of theft and whether damages can stack with injunctions were raised in a dispute that has already sent ripples across med tech.

Americas

Bayer enters COVID-19 vaccine row with three suits against major drugmakers

8 January 2026 Crop science division alleges that vaccine developers used patented mRNA stability technology in shots that earned them around $140 billion in global sales.

Europe

Who are the world’s best in-house counsel? Final call for the leading corporate IP professionals

8 January 2026 An inaugural, first-of-its-kind project by sister title WIPR aims to highlight the world’s leading in-house intellectual property counsel—and it needs your help.

More features

Key EU and UK regulatory changes to watch for in 2026

Regeneron v Alvotech: The big impact

Beyond traditional IP: A comprehensive AI strategy for life sciences

Prosecuting bispecific antibody patents: A cookbook for patent chefs

Novo Nordisk ramps up semaglutide defence as generics lurk

Novo Nordisk India strategy suffers semaglutide patent setback

EU Pharma Package hits the final stretch—but can negotiators agree?

The clinical trial dilemma: Navigating European practice

Biologics in India: bridging the gap

More on this story

Editor's picks

Editor's picks

More features